CSL Behring Wins Award for Efforts in Patient Access to HAE Treatment
Patient Access Awards chosen by payer and physician groups surveyed by MMIT
CSL Behring has won an award for its efforts to ensure patient access to therapies for hereditary angioedema (HAE).
The company received the nod in the Biologics & Injectables category of the Patient Access Awards, launched this year by Managed Markets Insight & Technology (MMIT), a provider of market access data and analytics. The awards were chosen by a group of payer and physician stakeholders who were surveyed as part of MMIT’s quarterly Biologics and Injectables Index.
CSL Behring is the manufacturer of Haegarda, the first preventive medication that can be injected under the skin to treat HAE. A biologic medication, it works by supplying the C1 inhibitor, which is missing in people with HAE and whose deficiency leads to the symptoms such as frequent swelling attacks.
Biologic therapies, or biologics, are products made from living organisms or that contain components of living organisms.
“As a company, we are committed to delivering on our promise to patients and we’ve recognized that this goes beyond just providing innovative treatments but also helping patients access their therapies,” Robert Rouse, CSL Behring’s head of US Market Access, said in a company press release.
“I’m particularly proud of this accomplishment as patient focus is always top of mind and this award highlights the great work we are doing on behalf of the patients we serve,” Rouse added.
The award winners, pharmaceutical manufacturers, were those given the highest ratings by the panelists within a given therapeutic area. The criteria included patient access services, account representative support, support programs for patients and their families, copay assistance, physician education, and coordinated support services, also known as Hub services. Hub services allow manufacturers to maintain a connection with patients during the prescription delivery process.
The other winners in the category included Novartis for its work targeting the neurogenerative disorder multiple sclerosis, Janssen Pharmaceuticals for the autoimmune condition rheumatoid arthritis, and Pfizer for growth hormone deficiency.
MMIT also granted awards within the area of cancer, which were chosen by stakeholders participating in its quarterly Oncology Index. The winners included Novartis for its work in breast cancer, Merck for metastatic melanoma, and Bristol-Myers Squibb for its work in non-small cell lung cancer and bladder cancer.
About the Author
